Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer.
暂无分享,去创建一个
Jose Belderbos | Walter J Curran | Rodrigo Arriagada | Anne Aupérin | Takeharu Yamanaka | Sarah Burdett | W. Curran | L. Stewart | T. Yamanaka | S. Burdett | R. Arriagada | J. Pignon | R. Paulus | J. Belderbos | P. Fournel | A. Aupérin | E. Rolland | K. Furuse | G. Clamon | H. C. Ulutin | C. Le Péchoux | M. Bozonnat | Rebecca Paulus | Xiaofei Wang | Jean-Pierre Pignon | Xiaofei Wang | Lesley Stewart | Pierre Fournel | A. Uitterhoeve | Estelle Rolland | Marie-Cecile Bozonnat | Cecile Le Péchoux | Kiyoyuki Furuse | Gerald Clamon | Hakki Cuneyt Ulutin | Apollonia Uitterhoeve
[1] F. Khuri,et al. Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] M Schemper,et al. A note on quantifying follow-up in studies of failure time. , 1996, Controlled clinical trials.
[3] J. Crowley,et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] S. Kudoh,et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] R. Gray. A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .
[6] J. Shamash,et al. A Brief Report on the Safety Study of Induction Chemotherapy Followed by Synchronous Radiotherapy and Cetuximab in Stage III Non-small Cell Lung Cancer (NSCLC): SCRATCH Study , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[7] J. Daurès,et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01 Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] J. Herndon,et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] R. Arriagada,et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. , 1991, Journal of the National Cancer Institute.
[10] K. Oysul,et al. Split-course radiotherapy with or without concurrent or sequential chemotherapy in non-small cell lung cancer. , 2000, Radiation medicine.
[11] B. Jeremic,et al. Report from the International Atomic Energy Agency (IAEA) consultants' meeting on elective nodal irradiation in lung cancer: non-small-Cell lung cancer (NSCLC). , 2008, International journal of radiation oncology, biology, physics.
[12] B. Jeremic,et al. Induction chemotherapy before chemoradiation in locally advanced non-small-cell lung cancer: failure after failure, again and again. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] A. Hogg,et al. High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. , 2001, International journal of radiation oncology, biology, physics.
[14] Suresh Senan,et al. Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[15] R. Livingston,et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] J. Pignon,et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[17] J. Herndon,et al. A feasibility study of extended chemotherapy for locally advanced non-small cell lung cancer: a phase II trial of cancer and leukemia group B. , 1994, Cancer investigation.
[18] Thomas J. Smith,et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] O. Brodin,et al. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials , 1995 .
[20] S. Thompson,et al. Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.
[21] J. Crowley,et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] D. Hayes,et al. Induction Chemotherapy with Carboplatin, Irinotecan, and Paclitaxel Followed by High Dose Three-Dimension Conformal Thoracic Radiotherapy (74 Gy) with Concurrent Carboplatin, Paclitaxel, and Gefitinib in Unresectable Stage IIIA and Stage IIIB Non-small Cell Lung Cancer , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[23] A. D. Schryver,et al. Systemic treatment of early breast-cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 women: 1 , 1992 .
[24] W. Curran,et al. A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage IIIA/B non-small cell lung cancer (NSCLC): A report of the 2 year and median survival (MS) for the RTOG 0324 trial , 2008 .
[25] J. Pignon,et al. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. , 2004, JAMA.
[26] Cynthia S. Johnson,et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] H. Groen,et al. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[28] T. Pajak,et al. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) , 1995, International journal of radiation oncology, biology, physics.
[29] W. Curran,et al. Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience. , 2005, International journal of radiation oncology, biology, physics.
[30] H. Thames,et al. Biased methods for estimating local and distant failure rates in breast carcinoma and a “commonsense” approach , 2001, Cancer.
[31] W. Hong,et al. Dose escalation of gemcitabine is possible with concurrent chest three-dimensional rather than two-dimensional radiotherapy: a phase I trial in patients with stage III non-small-cell lung cancer. , 2009, International journal of radiation oncology, biology, physics.
[32] G. Giaccone,et al. Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). , 2007, European journal of cancer.
[33] Anthony Howell,et al. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. , 1992 .
[34] Ladislav Pecen,et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. , 2004, Lung cancer.
[35] J. Battermann,et al. Accelerated regrowth of non-small-cell lung tumours after induction chemotherapy , 2003, British Journal of Cancer.
[36] Mike Clarke,et al. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992 .
[37] R. Salgia,et al. A Phase I Study of Pemetrexed, Carboplatin, and Concurrent Radiotherapy in Patients with Locally Advanced or Metastatic Non–Small Cell Lung or Esophageal Cancer , 2007, Clinical Cancer Research.